Based on the mapping of ARG2 expression in human cancer (https://www.proteinatlas.org/ENSG00000081181-ARG2/pathology, accessed on 9 August 2022) and literature data, we might anticipate that patients with prostate [65,74], renal [42], and pancreatic cancers [17,18], as well as chronic and acute myeloid leukaemia [13,54], could particularly benefit from ARG2 inhibition. Here, ARG2 is linked to familial pancreatic carcinoma.